Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AIDS Drugs Show More Promise For Preventing New Infections

By MARILYNN MARCHIONE AP CHIEF MEDICAL WRITER | July 30, 2018

New research shows more promise for using AIDS treatment drugs as a prevention tool, to help keep uninfected people from catching HIV during sex with a partner who has the virus.

There were no infections among gay men who used a two-drug combo pill either daily or just before and after sex with someone with HIV, one study found. In a second study, no uninfected men caught the virus if they had sex only with a partner whose HIV was well suppressed by medicines.

Both studies were discussed Tuesday at the International AIDS conference in Amsterdam.

The United States’ top AIDS scientist, Dr. Anthony Fauci, called the results “very impressive” and “really striking.”

About 36 million people worldwide have HIV and 1.8 million new infections occur each year, said Fauci, director of the National Institute of Allergy and Infectious Diseases.

“The only way you’re going to end the epidemic is by preventing additional cases of transmission,” he said. The treatment drugs are “tools that, if widely implemented, theoretically could end the epidemic.”

Expanding access to them is not only humanitarian but also smart policy, Fauci added.

“You get a twofer: You save the life of the person who’s infected … and you’re making it virtually impossible for that person to transmit that infection to their sexual partner.”

Until there’s a vaccine, condoms are the best way to prevent HIV infection, but not everyone uses them or does so all the time, so other options are needed.

A two-drug combo used to treat people with HIV, sold as Truvada by Gilead Sciences and in generic form in some countries, has been shown to help prevent infection when one partner has the virus and one does not, but the evidence so far has been strongest for male-female couples.

A new study was designed as a real-world test in about 1,600 gay men in the Paris region who were at high risk of getting HIV because of many sex partners, reluctance to use condoms or other reasons. They were offered the preventive pills either for daily use, as is recommended in the United States, or “on demand” — before and after unprotected sex. A little more than half chose on demand, and have been tested every three months to see if they had caught HIV.

“Since we started a year ago, we have not seen a single infection,” said the study leader, Dr. Jean-Michel Molina of Saint Louis Hospital in Paris. “On-demand seems to be at least as effective as daily when it’s used in real life.”

No one stopped using the drugs because of side effects.

“Now we can have just as much confidence in the power of treatment as prevention for gay male couples as we have had for heterosexual couples,” said Dr. Linda-Gail Bekker, AIDS conference chief and deputy director of the Desmond Tutu HIV Center at the University of Cape Town in South Africa.

The second study tested a different approach — keeping an infected partner’s virus severely suppressed with HIV medicines, which is known to greatly reduce the risk of spreading it.

Dr. Alison Rodger of University College London led a study of 779 gay male couples in 14 European countries where one partner was uninfected and the other was taking drugs to suppress HIV. They were tested every six to 12 months to see if the infected partner still had the virus under control, and whether the other partner had caught it.

After a median of 18 months, none of the infected men spread HIV to their partner, despite about 75,000 sex acts without condoms. There were 17 new HIV infections among men who were uninfected when the study started; tests showed those infections were from sex with someone other than the partner in the study.

(Source: Associated Press; Image credit: AP Photo/Jeff Chiu)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE